巨细胞性心肌炎诊疗进展  

Advances in the Diagnosis and Treatment of Giant Cell Myocarditis

作　　者：宫婷[1,2] 尤宏钊 康连鸣 GONG Ting;YOU Hongzhao;KANG Lianming(Department of Cardiology,National Center for Cardiovascular Diseases and Fuwai hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China;Heart Center,Beijing Chest Hospital,Capital Medical University,Beijing 100049,China)

机构地区：[1]中国医学科学院北京协和医学院,国家心血管病中心,阜外医院心内科,北京市100037 [2]首都医科大学附属北京胸科医院心脏中心,北京市100049

出　　处：《中国分子心脏病学杂志》2023年第5期5694-5698,共5页Molecular Cardiology of China

基　　金：中国医学科学院青年科学基金(2022-FWQN08)。

摘　　要：巨细胞性心肌炎(giant cell myocarditis,GCM)是一种罕见的疾病,病情进展迅速,好发于中青年,最主要的病理学改变为多核巨细胞混合心肌浸润和心肌细胞坏死。目前潜在的病理生理机制尚未明确,通常与自身免疫疾病相关或被认为是自身免疫疾病[1]。由于GCM临床表现缺乏特异性,诊断具有一定难度,心内膜心肌活检是确诊的金标准。本文将对GCM的最新定义、病理变化、诊断标准及治疗进展进行阐述。Giant cell myocarditis is a rare disease that progresses rapidly and often occurs in middle-aged adults.The main pathological changes are mixed myocardial infiltration of multinucleated giant cells and myocardial cell necrosis.The potential pathophysiological mechanisms are currently unclear and usually associated with or considered antoimmune diseases.The clinical manifestations of giant cell myocarditis are non-specific and the diagnosis is difficult.Endomyocardial biopsy is the golden standard for diagnosis.This article reviews the latest definition,pathological changes,diagnostic criteria and treatment progress.

关 键 词：巨细胞性心肌炎 心内膜心肌活检 免疫抑制治疗 

分 类 号：R542.21[医药卫生—心血管疾病]